Core Insights - electroCore, Inc. reported first quarter 2025 net sales of $6.7 million, a 23% increase compared to $5.4 million in the same period of 2024 [3][6] - The company closed the acquisition of NeuroMetrix, which is expected to enhance its position in the non-invasive bioelectronic technology market [2][6] - The CEO highlighted a 29% growth in total revenue excluding TAC-STIM, indicating strong performance in core product lines [2][6] Financial Performance - Gross profit for the first quarter of 2025 was $5.7 million, representing an 85% gross margin, compared to $4.6 million and 84% gross margin in the first quarter of 2024 [4][18] - Total operating expenses increased to approximately $9.5 million from $8.4 million in the first quarter of 2024, driven by higher selling, general, and administrative expenses [5][6] - The GAAP net loss for the first quarter of 2025 was $3.9 million, or a loss of $0.47 per share, compared to a net loss of $3.5 million, or a loss of $0.53 per share, in the first quarter of 2024 [8][18] Revenue Breakdown - Sales of prescription gammaCore to the U.S. Department of Veterans Affairs (VA) reached $4.7 million, a 22% increase from $3.9 million in the prior year [4] - International sales grew by 14%, with total sales outside the United States amounting to $513,000 [4] - Truvaga wellness products saw significant growth, with sales increasing by 187% to $1.1 million compared to $385,000 in the first quarter of 2024 [4] Guidance and Outlook - For the full year 2025, the company expects total revenue to be approximately $30 million, with net cash used for the next three quarters projected between $3.8 million and $4.3 million [12] - The acquisition of NeuroMetrix is anticipated to contribute meaningful revenue by the end of 2025, expanding the company's product offerings [12]

Core Insights - The merger between electroCore, Inc. and NeuroMetrix, Inc. has been completed, enhancing electroCore's position in the bioelectronic technology market focused on non-invasive health solutions [1][3] - The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio and is expected to significantly increase its addressable market for chronic pain and wellness treatments [2][3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company dedicated to improving health and quality of life through innovative non-invasive technologies [5] - Following the merger, NeuroMetrix will become an indirect wholly-owned subsidiary of electroCore, with its shares being de-listed from the Nasdaq Capital Market [3][7] Market Position and Strategy - The merger allows electroCore to leverage established distribution channels, particularly within the VA Hospital System, to accelerate the adoption of the Quell Fibromyalgia solution [3] - The addition of the Quell solution diversifies electroCore's offerings in non-pharmaceutical, non-invasive nerve stimulation, reinforcing its leadership in the bioelectronic technology sector [3]

Core Insights - electroCore, Inc. announced that its flagship wellness product, Truvaga Plus, is now compatible with the Apple Health app, enhancing user experience and health management [1][2] - Truvaga Plus is a hand-held vagus nerve stimulator aimed at providing stress relief, improving sleep, enhancing peace of mind, and improving focus [1] - The integration with the Apple Health app allows users to track their health data, including their progress with Truvaga Plus, in a consolidated view [2] Product Features - Truvaga Plus enables users to log their feelings after each session, utilizing the State of Mind API to monitor mental wellbeing over time [2] - The Apple Health app provides a secure platform for users to store and access important health information, leveraging the privacy features of iPhones [3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive technologies [4]

Core Insights - electroCore, Inc. will report its financial results for Q1 2025 on May 7, 2025, after market close [1] - A webinar will be held at 4:30 PM EST on the same day to discuss the financial results and address investor questions [1] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on enhancing health and quality of life through innovative non-invasive technologies [2]